ASP Isotopes (ASPI) risk factors, FY2024 10-K

Other

1. 01Summary of the Material and Other Risks Associated with Our Business
2. 02Our current business is tied directly to the nuclear medicine and quantum computing industries and depends on our ability to successfully introduce our medical and other specialty isotopes to changing technology and a changing medical practice landscape
3. 03We currently have no sales attributable to isotopes, but we expect to be heavily dependent on a few large customers to generate a majority of our revenues from sales of our future isotopes. Our operating results could be adversely affected by a reduction in business with our future significant customers
4. 04Obtaining and maintaining our patent protection depends on compliance with various procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements

Risks Related to Our Limited Operating History, Financial Position and Need for Additional Capital

1. 05operate as a public company
2. 06Our future prospects are tied directly to the end markets that use our isotopes including the diagnostic medical imaging industry and depend on our ability to successfully introduce our isotopes and adapt to a changing technology and medical practice landscape
3. 07We may not realize the anticipated benefits of previous acquisitions
4. 08The acquisition of a controlling interest in PET Labs Pharmaceuticals may fail to result in anticipated benefits but has involved significant investment of financial and other resources
5. 09We currently have no sales attributable to enriched isotopes, but we expect to be heavily dependent on a few large customers to generate a majority of our revenues. Our operating results could be adversely affected by a reduction in business with our future significant customers
6. 10We will require substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations
7. 11As of December 31, 2024, our cash was approximately $61.9 million. We believe, based on our current operating plan, that our existing cash, will be sufficient to fund our operations for at least the next 12 months from the date the financial statements are issued
8. 12We are subject to credit counterparty risk which could have a material adverse effect on our business, results of operations, financial condition and cash flows
9. 13Raising additional capital or acquiring or licensing assets by issuing equity or debt securities may cause dilution to our stockholders, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights

Risks Related to the Development and Commercialization of Our Future Isotopes

1. 14The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our currently planned future isotopes, which may never occur
2. 15We rely on a limited number of suppliers to provide us components and a material interruption in supply could prevent or limit our ability to execute our strategic plan and development programs in the expected timeframe
3. 16Development activities at our facility in South Africa could be disrupted for a variety of reasons, which could prevent us from completing our development activities
4. 17Risks associated with the development of ASP technology for enrichment of isotopes could cause substantial delays in production of our future isotopes
5. 18Regulatory approval for production and distribution of radiopharmaceuticals used for medical imaging and therapeutic treatments may involve a lengthy and expensive process with an uncertain outcome
6. 19Our success depends on our future customers’ ability to successfully commercialize products that are produced from our isotopes
7. 20Our success depends on our ability to adapt to a rapidly changing competitive environment in the nuclear industry
8. 21We may explore strategic collaborations that may never materialize or may fail
9. 22If the market opportunities for our future enriched isotopes are smaller than we estimate (even assuming receipt of any required regulatory approval), our business may suffer
10. 23We face substantial competition, which may result in others discovering, developing or commercializing enriched isotopes before or more successfully than us
11. 24Even if the products that we or our customers may produce using the ASP technology receives regulatory approval, it may fail to achieve market acceptance by radiopharmacies, hospitals, clinics or others in the medical community necessary for commercial success
12. 25Our efforts to educate radiopharmacies, hospitals, clinics and others in the medical community on the benefits of our isotopes that we may produce using the ASP technology may require significant resources and may never be successful
13. 26Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any isotopes that we may produce
14. 27a decline in our share price

Risks Related to Regulatory Compliance

1. 28If technology developed for the purposes of enriching isotopes can be applied to the creation or development of weapons-grade materials, then our technology may be considered “dual use” technology and be subject to limitations on public disclosure or export

Risks Related to Our Intellectual Property

1. 29Our intellectual property is not protected through patents or formal copyright registration. As a result, we do not have the full benefit of patent or copyright laws to prevent others from replicating the ASP technology and Quantum Enrichment technology
2. 30We may be unable to adequately protect our intellectual property and proprietary rights and prevent others from making unauthorized use of our products and technology
3. 31agreements and other agreements pertaining to our technology and proprietary information will increase, and such breaches could have an adverse effect on our business and competitive position
4. 32Our ASP technology and Quantum Enrichment technology may be found to infringe third-party intellectual property rights
5. 33defend arbitration, litigation or administrative proceedings which may be costly whether we win or lose (and may be prohibitively expensive, particularly for a company of our size), and which could result in a substantial diversion of our financial and management resources
6. 34We may enter into collaboration agreements and strategic alliances, and we may not realize the anticipated benefits of such collaborations or alliances
7. 35collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property
8. 36If we are unable to obtain patent protection for our future isotopes, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets
9. 37whether the patent applications that we own or in-license will result in issued patents with claims that cover our future isotopes or uses thereof in the United States or in foreign countries
10. 38Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
11. 39Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business
12. 40We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
13. 41Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
14. 42Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information
15. 43If we use hazardous and chemical materials in a manner that causes injury or violates applicable law, we may be liable for damages

Risks Related to Our Business Operations, Employee Matters and Managing Growth

1. 44We are highly dependent on the services of our senior management team, and if we are not able to retain these members of our management team and recruit and retain additional management, clinical and scientific personnel, our business will be harmed
2. 45We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations
3. 46Our employees, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
4. 47We and our contractors are highly dependent on the performance of sub-contractors and other third parties
5. 48Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us
6. 49Our international operations subject us to risks of doing business in foreign countries, which could adversely affect our business, financial condition and results of operations
7. 50political or economic repercussions from terrorist activities, including the possibility of hyperinflationary conditions and political instability, may occur in certain countries in which we do business
8. 51Our tangible assets may be subject to defects in title
9. 52We are subject to foreign currency risks

Risks Related to Ownership of Our Common Stock

1. 53Short sellers may take actions that could drive down the market price of our common stock, which could also result in related regulatory and governmental scrutiny, among other effects
2. 54stock. Issuers, like us, whose common stock has historically had limited trading history or volumes and/or have been susceptible to relatively high volatility levels can be vulnerable to such short seller publications
3. 55We do not know whether an active, liquid and orderly trading market will develop for our Common Stock or what the market price of our Common Stock will be and as a result it may be difficult for you to sell your shares of our Common Stock
4. 56The price of our stock may be volatile, and you could lose all or part of your investment
5. 57other events or factors, many of which are beyond our control
6. 58We do not intend to pay dividends on our Common Stock, so any returns will be limited to the value of our stock
7. 59Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
8. 60As of December 31, 2024, we had a total of 72,068,059 shares of Common Stock outstanding. If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock in the public market, the trading price of our Common Stock could decline
9. 61Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
10. 62We have broad discretion in the use of our existing cash and cash equivalents and may not use them effectively
11. 63We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our Common Stock less attractive to investors
12. 64Delaware law and provisions in our certificate of incorporation and bylaws, as amended, could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
13. 65These provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock
14. 66any action asserting a claim that is governed by the internal affairs doctrine
15. 67We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives
16. 68We could be subject to securities class action litigation
17. 69Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our Common Stock
18. 70If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline